---
schema_version: "secwatch.filing_event.v1"
accession: "0001636282-26-000075"
form_type: "8-K"
ticker: "SYRE"
cik: "0001636282"
company_name: "Spyre Therapeutics, Inc."
filed_at: "2026-06-01T20:01:39+00:00"
generated_at: "2026-06-01T20:04:39.037188+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "medium"
source: SEC EDGAR
---

# Spyre Therapeutics expands SPY003 license field beyond IBD with dosing restrictions until 2028-2030

## Summary
- License field expanded from inflammatory bowel disease to all human disease indications.
- Monotherapy dosing for non-IBD indications restricted until June 1, 2030; combination until June 1, 2028.
- Restrictions may terminate earlier upon a Material Transaction (change of control, asset sale) by June 1, 2028.
- Paragon receives non-exclusive license under Spyre's cross-license patents for retained IL-23 antibodies.

## SEC filing metadata
- accession: 0001636282-26-000075
- form_type: 8-K
- ticker: SYRE
- cik: 0001636282
- company_name: Spyre Therapeutics, Inc.
- filed_at: 2026-06-01T20:01:39+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636282/000163628226000075/0001636282-26-000075-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636282/000163628226000075/syre-20260529.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001636282-26-000075
- JSON: https://secwatch.observer/filing/0001636282-26-000075.json
- Plain text: https://secwatch.observer/filing/0001636282-26-000075.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.